---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-124025"
form_type: "8-K"
ticker: "OTLK"
cik: "0001649989"
company_name: "Outlook Therapeutics, Inc."
filed_at: "2023-12-06T23:59:59+00:00"
generated_at: "2026-06-07T17:08:33.236910+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Outlook Therapeutics COO departs, named Senior Advisor in organizational realignment

## Summary
- Terry Dagnon ceased as Chief Operations Officer effective November 30, 2023.
- Appointed as Senior Advisor under company's strategic realignment for ONS-5010 priorities.
- Dagnon continues to receive current base salary and benefits under existing employment agreement.

## SEC filing metadata
- accession: 0001104659-23-124025
- form_type: 8-K
- ticker: OTLK
- cik: 0001649989
- company_name: Outlook Therapeutics, Inc.
- filed_at: 2023-12-06T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1649989/000110465923124025/0001104659-23-124025-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1649989/000110465923124025/tm2332305d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-124025
- JSON: https://secwatch.observer/filing/0001104659-23-124025.json
- Plain text: https://secwatch.observer/filing/0001104659-23-124025.txt

## Key facts
- Executive change
  Terry Dagnon was appointed as Senior Advisor at Outlook Therapeutics, Inc..
  - Action: appointed as Senior Advisor
  - Role: Senior Advisor
  source text: Terry Dagnon ceased to serve as the Company’s Chief Operations Officer and an executive officer of the Company and was appointed as Senior Advisor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1649989/000110465923124025/0001104659-23-124025-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.